Vascular endothelial growth factor inhibitors (VEGFIs) have transformed treatment paradigms for several malignancies. By ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologics has announced a settlement and license agreement with the ...

Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US ...

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon Biologics' Jobevne, a biosimilar of Avastin, approved by the FDA, expanding oncology portfolio and access to ...